Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
36 participants
OBSERVATIONAL
2021-09-01
2026-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Long-term Study for the Outcome of Pompe Disease
NCT02399748
A Long Term Follow up Study in Late-onset Pompe Disease
NCT00713245
Muscle Response to Enzyme Replacement Therapy in Pompe Disease
NCT00713453
Metabolic Syndrome and Insulin Resistance in Primary Aldosteronism
NCT00173082
Newborn Screening Assay of Pompe's Disease
NCT01758354
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
OTHER
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Alglucosidase Alfa
Standard dose: 20-25 mg/kg every other week; Higher dose: \>25 mg/kg every other week.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Currently receiving ERT with regular clinic visits
3. Agree to sign informed consent
Exclusion Criteria
2. Allergy to Myozyme
3. Refuse to sign informed consent
0 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Taipei Veterans General Hospital, Taiwan
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2021-02-019A
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.